Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Uterine Cervical Neoplasms × niraparib × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 4 Fallopian Tube Neoplasms 3 Breast Neoplasms 3 Prostatic Neoplasms 2 Neoplasms 2 Advanced Solid Tumor 2 Uterine Cervical Neoplasms 1 Urothelial Cancer 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Rectal Neoplasms 1 Pancreatic Adenocarcinoma 1 Oropharyngeal Neoplasms 1 Mouth Neoplasms 1 Lung Neoplasms 1 Laryngeal Diseases 1 Glioma 1 Carcinoma, Transitional Cell 1 Carcinoma, Squamous Cell 1 Advanced Solid Tumor, Adult 1

Interventions

pembrolizumab 13 Cisplatin 9 Cyclophosphamide 8 Carboplatin 8 fludarabine 6 Paclitaxel 6 Bevacizumab 6 aldesleukin 5 Nivolumab 5 toripalimab 4 tisotumab vedotin 4 fludarabine phosphate 4 Radiotherapy 4 Brachytherapy 4 spartalizumab 3 Topotecan 3 Ipilimumab 3 Interleukin-2 3 Fulvestrant 3 Docetaxel 3 enzalutamide 2 durvalumab 2 balstilimab 2 Injections 2 Gemcitabine 2 Celecoxib 2 Biopsy 2 tremelimumab 1 sintilimab 1 sargramostim 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03644342 2024-09-03

NIVIX

Baylor College of Medicine

Phase 1/2 Terminated

4 enrolled 8 charts

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡